Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2024-04, Vol.10 (1), p.26-26, Article 26
Main Authors: Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.
Format: Article
Language:English
Subjects:
692/4028/67/1347
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Breast cancer
Brief Communication
Cancer Research
Cancer therapies
Cell Biology
Chemotherapy
Clinical outcomes
Histology
Human Genetics
Marital status
Mastectomy
Medical prognosis
Medical research
Metropolitan areas
Oncology
Patients
Population-based studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors ( p  = 0.001 and p  
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-024-00634-6